Rare disease: a focus on metabolomics

References

• About rare disease. EURORDIS, Rare Disease Europe, website. [cited 2016 July 20]. Available from: www.eurordis.org/about-rare-diseases
   Google Scholar
• De Vrueh R, Baekelandt ERF, De Haan JMH Priority medicines for Europe and the world: “a public health approach to innovation.” WHO Background Paper 6.19. Rare Diseases; 2013. [cited 2016 July 20]. Available from: www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf
   Google Scholar
• Lyst of rare disease and synonims: listed in alphabetical order. Orphanet Report Series. 2016 Mar. [cited 2016 July 20]. Available from: www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf
   Google Scholar
• Richter T, Nestler-Parr S, Babela R, et al.; International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015;18(6):906–914.
   PubMed Web of Science ®Google Scholar
• Key statistics from the rare disease United Kingdom report ‘experiences of rare diseases: an insight from patients and families’. [cited 2016 July 20]. Available from: www.raredisease.org.uk/index.htm
   Google Scholar
• Prevalence and incidence of rare diseases: bibliographic data. Diseases listed by decreasing prevalence, incidence, or number of published cases. Orphanet Report Series, 2016 Mar. Available from: www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf
   Google Scholar
• Rodwell C, Aymé S. eds. 2014 report on the state of the art of rare disease activities in Europe. European Union; 2014 July. [cited 2016 July 20]. Available from: http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivities.pdf
   Google Scholar
• Engel PA, Bagal S, Broback M, et al. Physician and patient perceptions regarding physician training in rare diseases: the need for stronger educational initiatives for physicians. J Rare Dis. 2013;1(2):1–14.
   Google Scholar
• Medina S, Dominguez-Perles R, Gil JI, et al. Metabolomics and the diagnosis of human diseases -A guide to the markers and pathophysiological pathways affected. Curr Med Chem. 2014;21(7):823–848.
   PubMed Web of Science ®Google Scholar
• Johnston L, Thompson R, Turner C, et al. The impact of integrated omics technologies for patients with rare diseases. Expert Opin Orphan Drugs. 2014;2(11):1211–1219.
   Web of Science ®Google Scholar
• About orphan drugs. EURORDIS, Rare Disease Europe, website. [Last accessed 2016 July 20]. Available from: www.eurordis.org/about-orphan-drugs
   Google Scholar
• Lists of medicinal products for rare diseases in Europe. Orphanet Report Series. 2016 July. [cited 2016 July 20]. Available from: www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf
   Google Scholar
• List of medicines in development for rare diseases, 2016, PHRMA website. [cited 2016 July 20] Available from: http://phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf
   Google Scholar
• Nicholson JK, Lindon JC, Holmes E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological nuclear magnetic resonance spectroscopic data. Xenobiotica. 1999;29:1181–1189.
   PubMed Web of Science ®Google Scholar
• Kewal KJ. Role of metabolomics in personalized medicine. In: Kewal KJ, ed. Textbook of personalized medicine. 2nd ed. New York (NY): Humana Press; 2015. p. 169–178.
   Google Scholar
• Fiehn O. Metabolomics- the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–171.
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Van QN, Waybright TJ, et al. Analytical and statistical approaches to metabolomics research. J Sep Sci. 2009;32(13):2183–2199.
   PubMed Web of Science ®Google Scholar
• Seely EW, Solomon CG. Improving the prediction of preeclampsia. N Engl J Med. 2016;374:83–84.
   PubMed Web of Science ®Google Scholar
• Bock JL. Metabolic profiling of amniotic fluid by proton nuclear magnetic resonance spectroscopy: correlation with fetal maturation and other clinical variables. Clin Chem. 1994;40:56–61.
   PubMed Web of Science ®Google Scholar
• Bahado-Singh R, Akolekar R, Mandal R, et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med. 2012;25(10):1840–1847.
   PubMed Web of Science ®Google Scholar
• Kuc S, Koster MPH, Pennings JLA, et al. Metabolomics profiling for identification of novel potential markers in early prediction of preeclampsia. PLoS ONE. 2014;9(5):e98540.
   PubMed Web of Science ®Google Scholar
• Koster MP, Vreeken RJ, Harms AC, et al. First-trimester serum acylcarnitine levels to predict preeclampsia: a metabolomics approach. Dis Markers. 2015;2015:857108.
   PubMed Web of Science ®Google Scholar
• Bahado-Singh R, Syngelaki A, Akolekar R, et al. Validation of metabolomic models for prediction of early-onset preeclampsia. Am J Obstet Gynecol. 2015;213(4):530–530.
   PubMed Web of Science ®Google Scholar
• Graca G, Duarte IF, Barros AS, et al. Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res. 2010;9:6016–6024.
   PubMed Web of Science ®Google Scholar
• Amorini AM, Giorlandino C, Longo S, et al. Metabolic profile of amniotic fluid as a biochemical tool to screen for inborn errors of metabolism and fetal anomalies. Mol Cell Biochem. 2012;359:205–216.
   PubMed Web of Science ®Google Scholar
• Diaz SO, Barros AS, Goodfellow BJ, et al. Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res. 2013;12:2946–2957.
   PubMed Web of Science ®Google Scholar
• Trivedi K, Iles RK. Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry – dihydrouracil and progesterone in the metabolism of Down syndrome. Biomed Chromatogr. 2015;29:1173–1183.
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Akolekar R, Mandal R. Metabolomic analysis for first-trimester Down syndrome prediction. Am J Obstet Gynecol. 2013;208:371.e1-8.
   Web of Science ®Google Scholar
• Diaz SO, Pinto J, Graca G, et al. Metabolic biomarkers of prenatal disorders: an exploratory nuclear magnetic resonance metabonomics study of second trimester maternal urine and blood plasma. J Proteome Res. 2011;10:3732–3742.
   PubMed Web of Science ®Google Scholar
• Pinto J, Maciel E, Melo TS, et al. Maternal plasma phospholipids are altered in trisomy 21 cases and prior to preeclampsia and preterm outcomes. Rapid Commun Mass Spectrom. 2014;28:1635–1638.
   PubMed Web of Science ®Google Scholar
• Pinto J, Almeida LM, Martins AS, et al. Impact of fetal chromosomal disorders on maternal blood metabolome: toward new biomarkers? Am J Obstet Gynecol. 2015;213(6):841.e1-841.e15.
   Web of Science ®Google Scholar
• Jakóbkiewicz-Banecka J, Gabig-Cimińska M, Banecka-Majkutewicz Z, et al. Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases. Metab Brain Dis. 2014;29:1–8.
   PubMed Web of Science ®Google Scholar
• Platt FM, Boland B, Van Der Spoel AC. Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199:723–734.
   PubMed Web of Science ®Google Scholar
• McGovern MM, Desnick RJ. Lysosomal storage diseases. In: Goldman L, Eds. Cecil textbook of medicine. 21st ed. St. Louis: W.B. Saunders Company; 2000. p. 1104–1107.
   Google Scholar
• Lenders M, Hennermann JB, Kurschat C, et al. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88.
   PubMed Web of Science ®Google Scholar
• Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(30):1–49.
   PubMed Web of Science ®Google Scholar
• Sestito S, Ceravolo F, Concolino D. Anderson–Fabry disease in children. Curr Pharm Des. 2013;19(33):6037–6045.
   PubMed Web of Science ®Google Scholar
• Ramaswami U, Najafian B, Schieppati A, et al. Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol. 2010;5:365–370.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Waldek S, Benigni A, et al. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5(2):360−364.
   PubMed Web of Science ®Google Scholar
• Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci. 2008;105:2812–2817.
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Ntwari A, Clarke JTR, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta. 2010;411:1906–1914.
   PubMed Web of Science ®Google Scholar
• Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042−1049.
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Boutin M, Gagnon R, et al. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal Chem. 2012;84(6):2745–2753.
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Boutin M. Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study. Curr Med Chem. 2012;19(19):3241–3252.
   PubMed Web of Science ®Google Scholar
• Lavoie P, Boutin M, Auray-Blais C. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal Chem. 2013;85(3):1743–1752.
   PubMed Web of Science ®Google Scholar
• Dupont FO, Gagnon R, Boutin M, et al. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Curr Med Chem. 2013;20(2):280–288.
   PubMed Web of Science ®Google Scholar
• Manwaring V, Boutin M, Auray-Blais C. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients. Anal Chem. 2013;85(19):9039–9048.
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Blais CM, Ramaswami U, et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta. 2015;438:195–204.
   PubMed Web of Science ®Google Scholar
• Boutin M, Auray-Blais C. Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers. J Am Soc Mass Spectrom. 2015;26(3):499–510.
   PubMed Web of Science ®Google Scholar
• Classification of Inborn Errors of Metabolism. Society for the study of Inborn Errors of Metabolism (SSIEM), 2011. [cited 2016 july 20] Available from: www.ssiem.org/centralstore/resources/ssiemclassificationiem2011.pdf
   Google Scholar
• Dent CE. A study of the behaviour of some sixty amino-acids and other ninhydrin-reacting substances on phenol-collidine’ filter-paper chromatograms, with notes as to the occurrence of some of them in biological fluids. Biochem J. 1948;43(2):169–180.
   Web of Science ®Google Scholar
• Rashed MS, Ozand PT, Bucknall MP, et al. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res. 1995;38:324–331.
   PubMed Web of Science ®Google Scholar
• Mitchell G, Grompe M, Lambert M, e`t al. Hypertyrosinemia. In: Scriver C, Beaudet A, Sly W, et al., eds. The metabolic and molecular bases of inherited disease. Vol. II. New York (NY): McGraw-Hill, Inc.; 2001. pp. 1777–1806.
   Google Scholar
• Denne SC, Karn CA, Ahlrichs JA, et al. Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. J Clin Invest. 1996;97:746–754.
   PubMed Web of Science ®Google Scholar
• La MG, Malvagia S, Pasquini E, et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom. 2008;22:812–818.
   PubMed Web of Science ®Google Scholar
• Rizzo C, Boenzi S, Inglese R, et al. Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2014;429:30–33.
   PubMed Web of Science ®Google Scholar
• Marquardt G, Currier R, McHugh DM, et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med. 2012;14:648–655.
   PubMed Web of Science ®Google Scholar
• Miller MJ, Kennedy AD, Eckhart AD, et al. Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism. J Inherit Metab Dis. 2015;38:1029–1039.
   PubMed Web of Science ®Google Scholar
• Iles RA, Chalmers RA. Nuclear magnetic resonance spectroscopy in the study of inborn errors of metabolism. Clin Sci. 1988;74:1−10.
   PubMed Web of Science ®Google Scholar
• Holmes E, Foxall PJ, Spraul M, et al. 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-Hydroxyglutaric aciduria and maple syrup urine disease. J Pharm Biomed Anal. 1997;15:1647–1659.
   PubMed Web of Science ®Google Scholar
• Aygen S, Dürr U, Hegele P, et al. NMR-based screening for inborn errors of metabolism: initial results from a study on Turkish neonates. J Inherit Metab Dis Rep. 2014;16:101–111.
   Google Scholar
• Atzori L, Antonucci R, Barberini L, et al. 1H NMR-based metabolomic analysis of urine from preterm and term neonates. Front Biosci (Elite Ed). 2011;3:1005–1012.
   PubMedGoogle Scholar
• Fanos V, Benini D, Verlato G, et al. Efficacy and renal tolerability of ibuprofen versus indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol. 2005;19:187–193.
   PubMed Web of Science ®Google Scholar
• Antonucci R, Cuzzolin L, Arceri A, et al. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol. 2009;65:223–230.
   PubMed Web of Science ®Google Scholar
• Longini M, Perrone S, Vezzosi P, et al. Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure. Pediatr Nephrol. 2011;26:105–109.
   PubMed Web of Science ®Google Scholar
• Noori S, Patel D, Friedlich P, et al. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants. J Perinatol. 2009;29:553–557.
   PubMed Web of Science ®Google Scholar
• Evans N. Patent ductus arteriosus and effects of low oxygen saturation limits. J Perinatol. 2009;29:529–530.
   PubMed Web of Science ®Google Scholar
• El Hajjar M, Vaksmann G, Rakza T, et al. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed. 2005;90:F419–22.
   PubMed Web of Science ®Google Scholar
• Atzori L, Griffin JL, Noto A, et al. Review metabolomics: a new approach to drug delivery in perinatology. Curr Med Chem. 2012;19:4654–4661.
   PubMed Web of Science ®Google Scholar
• Mussap M, Antonucci R, Noto A, et al. The role of metabolomics in neonatal and pediatric laboratory medicine. Clin Chim Acta. 2013;426:127–138.
   PubMed Web of Science ®Google Scholar
• Atzori L, Barberini L, Lussu M, et al. Metabolomics and patent ductus arteriosus diagnosis: is 1H-NMR (nuclear magnetic resonace) spectroscopy of urine at birth predictive as ultrasound? J Matern Fetal Neonatal Med. 2011; 24(S):I (abstract).
   Google Scholar
• Ryckman KK, Dagle JM, Shchelochkov OA. Association of amino acids with common complications of prematurity. Pediatr Res. 2013;73(6):700–705.
   PubMed Web of Science ®Google Scholar
• Harper AE, Miller RH, Block KP. Branched-chain amino acid metabolism. Annu Rev Nutr. 1984;4:409–454.
   PubMed Web of Science ®Google Scholar
• Antonucci R, Bassareo P, Zaffanello M, et al. Patent ductus arteriosus in the preterm infant: new insights into pathogenesis and clinical management. J Matern-Fetal Neonatal Med. 2010;23(S3):34–37.
   PubMed Web of Science ®Google Scholar
• Fanos V, Pusceddu M, Dessı` A, et al. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics (Sao Paulo). 2011;66(12):2141–2149.
   PubMed Web of Science ®Google Scholar
• Graca G, Duarte IF, Barros AS, et al. 1H NMR based metabonomics of human amniotic fluid for the metabolic characterization of fetus malformations. J Proteome Res. 2009;8:4144–4150.
   PubMed Web of Science ®Google Scholar
• Graca G, Duarte IF, Barros AS, et al. Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res. 2010;9:6016–6024.
   PubMed Web of Science ®Google Scholar
• Graca G, Goodfellow BJ, Barros AS, et al. UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol Biosyst. 2012;8:1243–1254.
   PubMed Web of Science ®Google Scholar
• Graça G, Diaz SO, Pinto J, et al. Can biofluids metabolic profiling help to improve healthcare during pregnancy?. Spectrosc-Int J. 2012;27(5–6):515–523.
   Web of Science ®Google Scholar
• Palmas F, Fattuoni C, Noto A, et al. The choice of amniotic fluid in metabolomics for the monitoring of fetus health. Expert Rev Mol Diagn. 2016;16(4):473–486.
   PubMed Web of Science ®Google Scholar